Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83%

Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.

Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83%
Credit: Pharvaris
Already have an account? Sign in.